RxDoctor Payments Data

Gerald Hollander, MD

Cardiovascular Disease · Brooklyn, NYNPI 1689632069

Payments from drug & device makers

$239in general payments, 2019–2025

Across 10 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$68
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$48
  • Pfizer$47
  • Boston Scientific$38
  • Cook Medical LLC$23
  • Alnylam Pharmaceuticals Inc.$15

What the payments were for

  • Food & beverage$239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$239 in reported general payments places this provider in the 15th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$145,602
Medicare patients
2,068
Services billed
3,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$404,897
EntrestoSacubitril/Valsartan147$138,454
JardianceEmpagliflozin121$122,625
XareltoRivaroxaban40$34,034
Metformin Er GastricMetformin Hcl12$27,189
FarxigaDapagliflozin Propanediol29$24,929
MultaqDronedarone Hcl25$24,378
OzempicSemaglutide16$22,642
BrilintaTicagrelor19$11,216
Metoprolol Succinate664$9,536
Repatha SureclickEvolocumab13$8,640
Rosuvastatin Calcium486$8,336
VascepaIcosapent Ethyl14$7,227
PradaxaDabigatran Etexilate Mesylate17$4,498
Losartan Potassium334$3,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$404,897431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →